Latest News

ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder (MDD) at the 2019 American Psychiatric Association Annual Mee

Source link

Related posts

Electronic Caregiver Offers Modern Medical Alert Pendants: CES 2019


Photoplethysmography signal can detect diabetes


Aktualisierte Ergebnisse der SPARTAN-Studie zeigen Reduzierung des Mortalitätsrisikos um 25 Prozent durch die Behandlung von Patienten mit nicht metastasiertem, kastrationsresistentem Prostatakarzinom (nmCRPC) mit ERLEADA® (Apalutamid)


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy